Ann Marie Ocampo Francisco

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Simon Heller, John B. Buse, Miles Fisher et al. · The Lancet · 2012 · 401 citations

Type 1, Diabetes Management, Insulin Degludec +7

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Alan J. Garber, Allen B. King, Stefano Del Prato et al. · The Lancet · 2012 · 323 citations

Diabetes Management, Insulin Degludec, Diabetes +7

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco et al. · The Lancet · 2021 · 211 citations

Obesity, Metabolic Syndrome, Dose-finding Phase 2 +10

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)

Chantal Mathieu, Helena W. Rodbard, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2014 · 155 citations · Full text

Macrophage Content in Subcutaneous Adipose Tissue

Xiaoyuan Xu, Juraj Koška, Ann Marie Ocampo Francisco et al. · Diabetes · 2008 · 138 citations · Full text